Prev Arrow Stocks

Becton Dickinson and Company ($BDX) Stock Forecast: Down 1.0% Today

Morpher AI identified a bearish signal. The stock price may continue to fall based on the momentum of the negative news.

What is Becton Dickinson and Company?

BDX (Becton Dickinson) is a global medical technology company that manufactures and sells medical devices, instrument systems, and reagents.

Why is Becton Dickinson and Company going down?

BDX stock is down 1.0% on Nov 27, 2024 19:23

  • BDX experienced a bearish movement possibly due to the news of Embecta, a spinoff company, stopping its insulin patch pump program and planning restructuring.
  • Investors might be concerned about the implications of this decision on BDX's overall business strategy and potential impact on future revenue.
  • The positive news about Embecta's financial performance and stock jump could have diverted investor attention away from BDX, leading to a decline in BDX's stock price.
  • This unexpected development within the healthcare sector could have contributed to the bearish sentiment surrounding BDX today.

BDX Price Chart

BDX Technical Analysis

BDX News

Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps - Embecta ( NASDAQ:EMBC )

On Tuesday, Embecta Corp EMBC posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago. The company reported quarterly sales of $286.1 million, up 1.5% year over year, beating the consensus of $277 million.

https://www.benzinga.com/24/11/42197315/becton-dickinson-spinoff-embecta-stops-insulin-patch-pump-program-plans-restructuring-stock-jumps

0 News Article Image Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps - Embecta  ( NASDAQ:EMBC )

Becton Dickinson and Company Price History

27.10.2024 - BDX Stock was down 1.0%

  • BDX experienced a bearish movement possibly due to the news of Embecta, a spinoff company, stopping its insulin patch pump program and planning restructuring.
  • Investors might be concerned about the implications of this decision on BDX's overall business strategy and potential impact on future revenue.
  • The positive news about Embecta's financial performance and stock jump could have diverted investor attention away from BDX, leading to a decline in BDX's stock price.
  • This unexpected development within the healthcare sector could have contributed to the bearish sentiment surrounding BDX today.

07.10.2024 - BDX Stock was down 5.0%

  • Despite strong fourth-quarter sales and exceeding revenue estimates, BDX faced a downturn likely attributed to concerns over lower sales expectations in China and market dynamics in the bioscience and pharma sectors.
  • The introduction of the BD IO Vascular Access System, designed for quick vascular access in critical care scenarios, did not offset the prevailing market sentiment towards the stock.
  • Investors may be evaluating BDX against other companies like MMSI, potentially leading to selling pressure on the stock.
  • Although positive earnings surprises were noted, they may not have been enough to counter broader market worries, contributing to BDX's bearish performance despite its robust financial results.

26.05.2023 - BDX Stock was up 1.2%

  • BDX had a strong bullish movement due to the announcement of the sale of its Surgical Instrumentation platform to STERIS for $540 million.
  • The sale will allow BDX to allocate the cash proceeds for capital allocation priorities for a "durable growth profile."
  • This move could potentially lead to a shift in focus towards other areas of the medical technology industry for BDX.

09.10.2023 - BDX Stock was down 5.5%

  • BDX reported Q4 earnings that decreased from last year and missed Street estimates, which could have contributed to the bearish movement.
  • The company's earnings totaled $108 million, which fell short of expectations.
  • Despite revenue topping estimates, BDX missed estimated earnings by 0.29%.
  • Becton, Dickinson also announced a dividend increase, but this news did not seem to offset the negative sentiment surrounding the earnings miss.

30.05.2023 - BDX Stock was up 2.3%

  • BDX stock had a strong bullish movement today.
  • The stock was downgraded to "Hold" by StockNews.com.
  • BDX is considered one of the most undervalued blue-chip stocks to buy.
  • Over the past 20 years, BDX has outperformed the market, with an average annual return of 9.93%.
  • Combined assessment:
  • Despite the downgrade by StockNews.com, BDX had a strong bullish movement today, possibly driven by the overall positive sentiment in the stock market. The stock is considered undervalued and has a history of outperforming the market, which could have attracted investors.

03.04.2024 - BDX Stock was down 0.5%

  • Despite reporting strong second-quarter sales and surpassing earnings and revenue estimates, BDX's stock experienced a bearish movement.
  • The overall bullish market sentiment did not positively impact BDX on Thursday, hinting at a specific factor affecting the stock.
  • Investors may have been concerned about future growth prospects or external factors despite the positive financial results.
  • The contrast between optimistic analyst outlook and market movement implies underlying issues influencing investor sentiment towards BDX.

11.09.2023 - BDX Stock was down 1.8%

  • The bearish movement in BDX today could be attributed to the following factors:
  • 1. SevenBridge Financial Group LLC reducing its stake in BDX: The news of a major shareholder decreasing its holdings in the company might have raised concerns among investors, leading to a sell-off and downward pressure on the stock price.
  • 2. Mixed analyst sentiment: Despite Becton, Dickinson and Company's solid growth in Q3 driven by strong demand for its products, there might be some mixed opinions among analysts regarding the stock's future performance. This uncertainty could have contributed to the bearish movement.
  • 3. Overall market sentiment: It is also important to consider the broader market conditions. If there was a general bearish sentiment in the market today, it could have influenced the downward movement of BDX along with other stocks.
  • Please note that these assessments are based on the provided articles and may not capture all the factors influencing the stock's movement.

05.08.2023 - BDX Stock was down 1.2%

  • The bearish movement in BDX's stock today could be attributed to the following factors:
  • 1. Non-pharma healthcare focus: The article highlights the potential gains in non-pharma healthcare stocks. As BDX is a medical device manufacturer, it may not have been the top choice for investors seeking pharmaceutical-related investments, leading to a decrease in demand for the stock.
  • 2. Emerging themes in healthcare: The article mentions that utilization, digital healthcare, managed care, and medical services are emerging trends in the healthcare industry. If investors perceive BDX's products to be less aligned with these trends, it could have contributed to the bearish movement.
  • 3. Analyst ratings: The article mentions that the recommended stocks are rated "Overweight" or better by analysts. If BDX's stock does not receive a similarly positive rating, it could have influenced investor sentiment and contributed to the bearish movement.

03.05.2024 - BDX Stock was up 2.4%

  • BDX stock experienced a bullish movement after announcing the acquisition of Edwards Lifesciences' critical care business for $4.2 billion.
  • The market reacted positively to this strategic move, as it expands BDX's portfolio and strengthens its position in the healthcare industry.
  • The acquisition is seen as a smart investment by BDX to enhance its offerings and potentially drive future growth in the medical technology sector.
  • This news reflects investor confidence in BDX's strategic decisions and long-term prospects, contributing to the bullish movement in the stock price.

10.06.2024 - BDX Stock was up 0.1%

  • The bullish movement in BDX stock today could be attributed to the positive performance comparison with its competitors in the Health Care Equipment & Supplies industry.
  • Investors may be reacting favorably to the extensive industry analysis that highlights Boston Scientific's strong market standing, growth prospects, and key financial metrics.
  • The market may be optimistic about Boston Scientific's innovative products for medical procedures, such as angioplasty, cardiac rhythm management, and chronic pain treatment, which could drive future growth and profitability.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.